Kodiak Sciences Completes Enrollment in First Pivotal Cohort in the Phase 3 PEAK Trial of KSI-101 for Macular Edema Secondary to Inflammation and Reaffirms Topline Clinical Data Release Remains on Track for December 2026

The company reports enrollment of 300 subjects in its first pivotal cohort, with topline 24-week primary-endpoint data on track for a December 2026 release. It also completed enrollment for the second pivotal cohort at 600 subjects across the PEAK and PINNACLE studies, with completion expected in 4Q 2026. Overall, the update is progress-positive but still largely milestone/timeline driven with no efficacy/regulatory outcome yet.

Analysis

The company reports enrollment of 300 subjects in its first pivotal cohort, with topline 24-week primary-endpoint data on track for a December 2026 release. It also completed enrollment for the second pivotal cohort at 600 subjects across the PEAK and PINNACLE studies, with completion expected in 4Q 2026. Overall, the update is progress-positive but still largely milestone/timeline driven with no efficacy/regulatory outcome yet.